Retrieve available abstracts of 45 articles: HTML format
Single Articles
June 2025
MANDALA M, Amaral T, Rutkowski P, Sergi MC, et al Combined immunotherapy with nivolumab and ipilimumab with and without sequential
or concomitant stereotactic radiotherapy in patients with melanoma brain
metastasis: An international retrospective study.
Eur J Cancer. 2025;225:115567. PubMedAbstract available
May 2025
BLOEM M, Suijkerbuijk KPM, Aarts MJB, van den Berkmortel FWPJ, et al Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma
brain metastases: Results from the Dutch Melanoma Treatment Registry.
Eur J Cancer. 2025;223:115514. PubMedAbstract available
MORFOUACE M, Bielle F, Razis E, Estrade F, et al Molecular analysis of adolescent and young adult high grade gliomas in the
SPECTA-AYA study: Poorly characterised tumours with frequent germline
alterations.
Eur J Cancer. 2025;223:115493. PubMedAbstract available
VAN KESSEL E, Woerdman N, Pluim D, Kerklaan BM, et al Added prognostic value of circulating tumor cell numbers in CSF of patients with
leptomeningeal metastasis from epithelial tumors.
Eur J Cancer. 2025;220:115377. PubMedAbstract available
DESAI AV, Bagchi A, Armstrong AE, van Tilburg CM, et al Efficacy and safety of entrectinib in children with extracranial solid or central
nervous system (CNS) tumours harbouring NTRK or ROS1 fusions.
Eur J Cancer. 2025;220:115308. PubMedAbstract available
April 2025
LEIBETSEDER A, Berghoff AS Response to letter commenting on "Association of pregnancy with tumour
progression in patients with glioma".
Eur J Cancer. 2025 Apr 9:115411. doi: 10.1016/j.ejca.2025.115411. PubMed
DANG C, Liu P, Yu X Letter Re: Association of pregnancy with tumour progression in patients with
glioma.
Eur J Cancer. 2025 Apr 4:115410. doi: 10.1016/j.ejca.2025.115410. PubMed
March 2025
CAPASSO I, Perrone E, Duranti S, Giannarelli D, et al Are all mismatch repair deficient endometrial cancers created equal? A large,
retrospective, tertiary center experience.
Eur J Cancer. 2025;220:115344. PubMedAbstract available
January 2025
LEIBETSEDER A, Mair MJ, Serra AS, Spiro Z, et al Association of pregnancy with tumour progression in patients with glioma.
Eur J Cancer. 2025;218:115259. PubMedAbstract available
PEDERSEN S, Johansen EL, Hojholt KL, Pedersen MW, et al Survival improvements in patients with melanoma brain metastases and
leptomeningeal disease in the modern era: Insights from a nationwide study
(2015-2022).
Eur J Cancer. 2025;217:115253. PubMedAbstract available
PEARSON AD, Mueller S, Filbin MG, Grill J, et al Paediatric strategy forum for medicinal product development in diffuse midline
gliomas in children and adolescents ACCELERATE in collaboration with the European
Medicines Agency with participation of the Food and Drug Administration.
Eur J Cancer. 2025;217:115230. PubMedAbstract available
December 2024
DUERINCK J, Karschnia P, Broekman M, Gempt J, et al Addressing the role of surgery in brain tumour trials: A report from the
neurosurgery committee of the EORTC brain tumour group.
Eur J Cancer. 2024;216:115198. PubMedAbstract available
DI CARLO D, Annereau M, Vignes M, Denis L, et al Real life data of ONC201 (dordaviprone) in pediatric and adult H3K27-altered
recurrent diffuse midline glioma: Results of an international academia-driven
compassionate use program.
Eur J Cancer. 2024;216:115165. PubMedAbstract available
DE GROOT FA, Dekker TJA, Doorduijn JK, Bohringer S, et al Clinical characteristics and survival outcomes of patients with primary central
nervous system lymphoma treated with high-dose methotrexate-based
polychemotherapy and consolidation therapies.
Eur J Cancer. 2024;213:115068. PubMedAbstract available
November 2024
OORT Q, Reijneveld JC, Sikkes SAM, Koekkoek JAF, et al Instrumental activities of daily living in neuro-oncology: International
validation of the EORTC IADL-BN32 questionnaire.
Eur J Cancer. 2024;212:114335. PubMedAbstract available
September 2024
TSUCHIYA-KAWANO Y, Shiraishi Y, Tanaka K, Tachihara M, et al Nivolumab plus ipilimumab with chemotherapy for non-small cell lung cancer with
untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK
2004).
Eur J Cancer. 2024;212:115052. PubMedAbstract available
GERRITSEN JKW, Mekary RA, Pisica D, Zwarthoed RH, et al Onco-functional outcome after resection for eloquent glioblastoma (OFO): A
propensity-score matched analysis of an international, multicentre, cohort study.
Eur J Cancer. 2024;212:114311. PubMedAbstract available
July 2024
LE RHUN E, Weller M, Anders C, Larkin J, et al "Symptomatic" melanoma brain metastases: A call for clear definitions and
adoption of standardized tools.
Eur J Cancer. 2024;208:114202. PubMedAbstract available
June 2024
CHEW SM, Ferraro E, Safonov A, Chen Y, et al Impact of cyclin dependent kinase 4/6 inhibitors on breast cancer brain
metastasis outcomes.
Eur J Cancer. 2024;207:114175. PubMedAbstract available
May 2024
TRAMA A, Botta L, Stiller C, Visser O, et al Survival of European adolescents and young adults diagnosed with cancer in
2010-2014.
Eur J Cancer. 2024;202:113558. PubMedAbstract available
April 2024
LE RHUN E, Gorlia T, Felsberg J, Jongen J, et al Corrigendum to "Zotiraciclib (TG02) for newly diagnosed glioblastoma in the
elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial" [Eur J Cancer
198 (2024) 113475].
Eur J Cancer. 2024 Apr 23:114066. doi: 10.1016/j.ejca.2024.114066. PubMed
KATSUMATA S, Shimokawa M, Hamada A, Haratake N, et al Impact of central nervous system metastasis after complete resection of lung
adenocarcinomas harboring common EGFR mutation - A real-world database study in
Japan: The CReGYT-01 EGFR study.
Eur J Cancer. 2024;201:113951. PubMedAbstract available
March 2024
PICCA A, Touat M, Belin L, Gourmelon C, et al REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade
gliomas.
Eur J Cancer. 2024;202:114034. PubMedAbstract available
THOMAS-JOULIE A, Tran S, El Houari L, Seyve A, et al Prognosis of glioblastoma patients improves significantly over time interrogating
historical controls.
Eur J Cancer. 2024;202:114004. PubMedAbstract available
DI GIACOMO AM, Chiarion-Sileni V, Del Vecchio M, Ferrucci PF, et al Corrigendum to "Nivolumab plus ipilimumab in melanoma patients with asymptomatic
brain metastases: 7-year outcomes and quality of life from the multicenter phase
III NIBIT-M2 trial" [Eur J Cancer 199 (2024) 113531].
Eur J Cancer. 2024 Mar 8:113981. doi: 10.1016/j.ejca.2024.113981. PubMed
February 2024
STRATMANN JA, Althoff FC, Doebel P, Rauh J, et al Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter
real-world experience from the compassionate use program in Germany.
Eur J Cancer. 2024;201:113911. PubMedAbstract available
KOCHANEK C, Gilde C, Zimmer L, Ugurel S, et al Effects of an immunosuppressive therapy on the efficacy of immune checkpoint
inhibition in metastatic melanoma - An analysis of the prospective skin cancer
registry ADOREG.
Eur J Cancer. 2024;198:113508. PubMedAbstract available
January 2024
MANDALA M, Lorigan P, Sergi MC, Benannoune N, et al Combined immunotherapy in melanoma patients with brain metastases: A multicenter
international study.
Eur J Cancer. 2024;199:113542. PubMedAbstract available
DI GIACOMO AM, Chiarion-Sileni V, Del Vecchio M, Ferrucci PF, et al Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain
metastases: 7-year outcomes and quality of life from the multicenter phase III
NIBIT-M2 trial.
Eur J Cancer. 2024;199:113531. PubMedAbstract available
LI Z, Song Y, Farrukh Hameed NU, Yuan S, et al Effect of high-field iMRI guided resection in cerebral glioma surgery: A
randomized clinical trial.
Eur J Cancer. 2024;199:113528. PubMedAbstract available
HABRINGER S, Demel UM, Fietz AK, Lammer F, et al A prospective observational study of real-world treatment and outcome in
secondary CNS lymphoma.
Eur J Cancer. 2024;196:113436. PubMedAbstract available
WATANABE S, Furuya N, Nakamura A, Shiihara J, et al A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel
for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).
Eur J Cancer. 2024;197:113469. PubMedAbstract available
December 2023
LE RHUN E, Gorlia T, Felsberg J, Jongen J, et al Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for
recurrent glioblastoma: The EORTC 1608 STEAM trial.
Eur J Cancer. 2023;198:113475. PubMedAbstract available
STEMMER A, Margalit O, Serpas V, Strauss G, et al Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - Outcome
and novel predictive markers.
Eur J Cancer. 2023;198:113495. PubMedAbstract available
October 2023
LIU D, Wang J Re: Association between objective neurocognitive functioning and neurocognitive
complaints in recurrent high-grade glioma: Longitudinal evidence of cognitive
awareness from EORTC brain tumour trials.
Eur J Cancer. 2023 Oct 27:113385. doi: 10.1016/j.ejca.2023.113385. PubMed
September 2023
ROSSIDES M, Mogensen H, Kampitsi CE, Talback M, et al Parental occupational exposure to metals and risk of cancer in the offspring: A
register-based case-control study from Sweden.
Eur J Cancer. 2023;191:113243. PubMedAbstract available
August 2023
DOHM AE, Nakashima JY, Kalagotla H, Jiang SX, et al Stereotactic radiosurgery and anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy,
anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional
chemotherapy for the management of melanoma brain metastases.
Eur J Cancer. 2023;192:113287. PubMedAbstract available
SOUSSAIN C, Malaise D, Choquet S, Ghesquieres H, et al Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary
CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results
of the iLOC study by the Lymphoma Study Association (LYSA) and the French
Oculo-Cerebral L
Eur J Cancer. 2023;189:112909. PubMed
June 2023
PADOVAN M, Maccari M, Bosio A, De Toni C, et al Actionable molecular alterations in newly diagnosed and recurrent IDH1/2
wild-type glioblastoma patients and therapeutic implications: a large
mono-institutional experience using extensive next-generation sequencing
analysis.
Eur J Cancer. 2023;191:112959. PubMedAbstract available
REIJNEVELD JC, Machingura A, Coens C, Taphoorn MJB, et al Health-related quality-of-life results from the randomised phase II TAVAREC trial
on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence
World Health Organization grade 2 and 3 glioma (European Organization for
Research and Trea
Eur J Cancer. 2023;190:112946. PubMedAbstract available
May 2023
DESMOULINS I, Bellio H, Mejean N, Truntzer C, et al Intracranial response of brain metastases in patients with HER2-amplified breast
cancer treated with trastuzumab-deruxtecan after failure of tucatinib-based
therapy.
Eur J Cancer. 2023;187:161-163. PubMed
HERTLER C, Felsberg J, Gramatzki D, Le Rhun E, et al Long-term survival with IDH wildtype glioblastoma: first results from the
ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419).
Eur J Cancer. 2023 May 8:S0959-8049(23)00230-7. doi: 10.1016/j.ejca.2023. PubMedAbstract available
April 2023
ALAFANDI A, van Garderen KA, Klein S, van der Voort SR, et al Association of pre-radiotherapy tumour burden and overall survival in newly
diagnosed glioblastoma adjusted for MGMT promoter methylation status.
Eur J Cancer. 2023;188:122-130. PubMedAbstract available
MANACORDA S, Carmena MT, Malone C, Linh Le HM, et al Ipilimumab plus nivolumab in patients with symptomatic melanoma brain metastasis
requiring corticosteroids.
Eur J Cancer. 2023;188:98-107. PubMedAbstract available
March 2023
CARAMANNA I, Reijneveld JC, van de Ven PM, van den Bent M, et al Association between objective neurocognitive functioning and neurocognitive
complaints in recurrent high-grade glioma: Longitudinal evidence of cognitive
awareness from EORTC brain tumour trials.
Eur J Cancer. 2023;186:38-51. PubMedAbstract available